Ipriflavone From Aquilaria malaccensis Lam. Exosome-Like Nanoparticles Targets Prolyl Hydroxylase Domain Protein 2 (PHD2) to Enhance Hypoxia-Inducible Factor-α (HIF-α) Hydroxylation Thereby Alleviating Hypoxia-Induced Gastrointestinal Mucosal Ferroptosis

Abstract

The major challenge in the clinical treatment of gastrointestinal mucosal injury caused by high-altitude hypoxic environments lies in its unclear underlying mechanisms. In the previous study, we found that hypoxia-induced gastric and small intestinal damage was mainly attributable to ferroptosis mediated by hypoxia-inducible factor-α (HIF-α; mainly HIF-1α and HIF-2α). Both plant exosome-like nanoparticles and Aquilaria malaccensis Lam. have been reported to have antioxidant properties. In the present study, orally delivered A. malaccensis Lam. exosome-like nanoparticles (AELNs) reduced HIF-1α expression and alleviated gastric and small intestinal mucosal ferroptosis induced by hypoxia. We analyzed the compositions of AELNs and hypothesized that ipriflavone was the effector component, as it showed the highest abundance of metabolites. Subsequent experiments demonstrated that ipriflavone downregulated polyunsaturated fatty acid-phospholipids, NADPH oxidase 4 (NOX4), and arachidonate 5-lipoxygenase (ALOX5) by inhibiting HIF-α, consequently alleviating hypoxia-induced gastric and small intestinal mucosal ferroptosis. Ipriflavone was found to inhibit HIF-α by targeting prolyl hydroxylase domain protein 2 (PHD2) to induce it to hydroxylate HIF-α. This study highlights that ipriflavone, a potent HIF-α inhibitor, significantly ameliorates the gastric and small intestinal mucosal damage caused by hypoxia and has promise in clinical applications for treating disorders characterized by high levels of HIF-α.

Keywords

Aquilaria malaccensis Lam. exosome-like nanoparticles (AELNs) / ferroptosis / hypoxia / hypoxia-inducible factor-α (HIF-α) / ipriflavone / prolyl hydroxylase domain protein 2 (PHD2)

References

[1] A. C. Anand, V. K. Sashindran, and L. Mohan, “Gastrointestinal Problems at High Altitude,” Tropical Gastroenterology 27, no. 4 (2006): 147–153.

[2] Z. J. McKenna, F. Gorini Pereira, T. L. Gillum, F. T. Amorim, M. R. Deyhle, and C. M. Mermier, “High-Altitude Exposures and Intestinal Barrier Dysfunction,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 322, no. 3 (2022): R192–R203.

[3] V. L. Dengler, M. Galbraith, and J. M. Espinosa, “Transcriptional Regulation by Hypoxia Inducible Factors,” Critical Reviews in Biochemistry and Molecular Biology 49, no. 1 (2014): 1–15.

[4] P. Lee, N. S. Chandel, and M. C. Simon, “Cellular Adaptation to Hypoxia Through Hypoxia Inducible Factors and Beyond,” Nature Reviews Molecular Cell Biology 21, no. 5 (2020): 268–283.

[5] A. Ginouvès, K. Ilc, N. Macías, J. Pouysségur, and E. Berra, “PHDs Overactivation During Chronic Hypoxia “Desensitizes” HIFα and Protects Cells From Necrosis,” PNAS 105, no. 12 (2008): 4745–4750.

[6] R. Singhal and Y. M. Shah, “Oxygen Battle in the Gut: Hypoxia and Hypoxia-Inducible Factors in Metabolic and Inflammatory Responses in the Intestine,” Journal of Biological Chemistry 295, no. 30 (2020): 10493–10505.

[7] E. Berra, E. Benizri, A. Ginouvès, et al., “HIF Prolyl-Hydroxylase 2 Is the Key Oxygen Sensor Setting Low Steady-State Levels of HIF-1alpha in Normoxia,” EMBO Journal 22, no. 16 (2003): 4082–4090.

[8] K. Takeda, H. L. Aguila, N. S. Parikh, et al., “Regulation of Adult Erythropoiesis by Prolyl Hydroxylase Domain Proteins,” Blood 111, no. 6 (2008): 3229–3235.

[9] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, et al., “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease,” Cell 171, no. 2 (2017): 273–285.

[10] D. Tang, X. Chen, R. Kang, and G. Kroemer, “Ferroptosis: Molecular Mechanisms and Health Implications,” Cell Research 31, no. 2 (2021): 107–125.

[11] X. Zheng, Y. Liang, and C. Zhang, “Ferroptosis Regulated by Hypoxia in Cells,” Cells 12, no. 7 (2023): 1050.

[12] C. Peng, X. Li, F. Ao, et al., “Mitochondrial ROS Driven by NOX4 Upregulation Promotes Hepatocellular Carcinoma Cell Survival After Incomplete Radiofrequency Ablation by Inducing of Mitophagy via Nrf2/PINK1,” Journal of Translational Medicine 21, no. 1 (2023): 218.

[13] Q. Y. Sun, H. H. Zhou, and X. Y. Mao, “Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death,” Oxidative Medicine and Cellular Longevity 2019 (2019): 2749173.

[14] D. Wang, H. Zhang, X. Liao, et al., “Oral Administration of Robinia pseudoacacia L. Flower Exosome-Like Nanoparticles Attenuates Gastric and Small Intestinal Mucosal Ferroptosis Caused by Hypoxia Through Inhibiting HIF-1α- and HIF-2α-Mediated Lipid Peroxidation,” Journal of Nanobiotechnology 22, no. 1 (2024): 479.

[15] G. He, R. A. Shankar, M. Chzhan, et al., “Noninvasive Measurement of Anatomic Structure and Intraluminal Oxygenation in the Gastrointestinal Tract of Living Mice With Spatial and Spectral EPR Imaging,” PNAS 96, no. 8 (1999): 4586–4591.

[16] Y. Z. Hashim, P. G. Kerr, P. Abbas, and H. M. Salleh, “Aquilaria spp. (Agarwood) as Source of Health Beneficial Compounds: A Review of Traditional Use, Phytochemistry and Pharmacology,” Journal of Ethnopharmacology 189 (2016): 331–360.

[17] S. Ma, M. Huang, Y. Fu, M. Qiao, and Y. Li, “How Closely Does Induced Agarwood's Biological Activity Resemble That of Wild Agarwood?,” Molecules 28, no. 7 (2023): 2922.

[18] Z. Zhang, Y. Yu, G. Zhu, et al., “The Emerging Role of Plant-Derived Exosomes-Like Nanoparticles in Immune Regulation and Periodontitis Treatment,” Frontiers in Immunology 13 (2022): 896745.

[19] Y. Teng, Y. Ren, M. Sayed, et al., “Plant-Derived Exosomal MicroRNAs Shape the Gut Microbiota,” Cell Host & Microbe 24, no. 5 (2018): 637–652.e638.

[20] S. Ju, J. Mu, T. Dokland, et al., “Grape Exosome-Like Nanoparticles Induce Intestinal Stem Cells and Protect Mice From DSS-Induced Colitis,” Molecular Therapy 21, no. 7 (2013): 1345–1357.

[21] R. A. Gad, E. S. Abdel-Reheim, G. M. G. Shehab, H. S. Hafez, and A. S. A. Abuelsaad, “Evaluation of Insulin Resistance Induced Brain Tissue Dysfunction in Obese Dams and Their Neonates: Role of Ipriflavone Amelioration,” Combinatorial Chemistry & High Throughput Screening 24, no. 6 (2021): 767–780.

[22] H. Koike, Y. Nishida, T. Shinomura, et al., “Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase,” International Journal of Molecular Sciences 23, no. 8 (2022): 4089.

[23] Z. Xiao, C. Huang, J. Wu, et al., “The Neuroprotective Effects of Ipriflavone Against H₂O₂ and Amyloid Beta Induced Toxicity in Human Neuroblastoma SH-SY5Y Cells,” European Journal of Pharmacology 721, no. 1–3 (2013): 286–293.

[24] Q. Hu, C. Long, D. Wu, et al., “The Efficacy and Safety of Ipriflavone in Postmenopausal Women With Osteopenia or Osteoporosis: A Systematic Review and Meta-Analysis,” Pharmacological Research 159 (2020): 104860.

[25] H. S. Hafez, D. A. Ghareeb, S. R. Saleh, et al., “Neuroprotective Effect of Ipriflavone Against Scopolamine-Induced Memory Impairment in Rats,” Psychopharmacology 234, no. 20 (2017): 3037–3053.

[26] R. Nie, J. Lu, R. Xu, et al., “Ipriflavone as a Non-Steroidal Glucocorticoid Receptor Antagonist Ameliorates Diabetic Cognitive Impairment in Mice,” Aging Cell 21, no. 3 (2022): e13572.

[27] D. Marchi and F. J. M. van Eeden, “Homeostatic Regulation of Glucocorticoid Receptor Activity by Hypoxia-Inducible Factor 1: From Physiology to Clinic,” Cells 10, no. 12 (2021): 3441.

[28] J. Rodencal and S. J. Dixon, “A Tale of Two Lipids: Lipid Unsaturation Commands Ferroptosis Sensitivity,” Proteomics 23, no. 6 (2023): e2100308.

[29] Y. Zou, M. J. Palte, A. A. Deik, et al., “A GPX4-Dependent Cancer Cell State Underlies the Clear-Cell Morphology and Confers Sensitivity to Ferroptosis,” Nature Communications 10, no. 1 (2019): 1617.

[30] B. R. Stockwell, “Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications,” Cell 185, no. 14 (2022): 2401–2421.

[31] Z. Song, X. Wang, J. Zeng, et al., “DHA and EPA Exacerbate Hypoxia-Induced Ferroptosis in Gastric and Small Intestinal Mucosa by Disrupting the Balance Between SLC7A11 Upregulation and PUFA-PL Accumulation,” Journal of Lipid Research 66, no. 9 (2025): 100876.

[32] D. Huang, J. Chen, M. Zhao, et al., “Plant-Derived Extracellular Vesicles: Composition, Function and Clinical Potential,” Journal of Translational Medicine 23, no. 1 (2025): 1065, https://doi.org/10.1186/s12967-025-07101-1.

[33] V. Chobot, S. Drage, and F. Hadacek, “Redox Properties of 8-Quinolinol and Implications for Its Mode of Action,” Natural Products Communications 6, no. 5 (2011): 597–602.

[34] H. Tominaga, H. Katoh, K. Odagiri, et al., “Different Effects of Palmitoyl-L-Carnitine and Palmitoyl-CoA on Mitochondrial Function in Rat Ventricular Myocytes,” American Journal of Physiology-Heart and Circulatory Physiology 295, no. 1 (2008): H105–H112.

[35] X. L. Yan, X. C. Liu, Y. N. Zhang, et al., “Succinate Aggravates Intestinal Injury in Mice With Necrotizing Enterocolitis,” Frontiers in Cellular and Infection Microbiology 12 (2022): 1064462.

[36] T. Szemes, B. Vlkova, G. Minarik, et al., “On the Origin of Reactive Oxygen Species and Antioxidative Mechanisms in Enterococcus faecalis,” Redox Report: Communications in Free Radical Research 15, no. 5 (2010): 202–206.

[37] S. Di Gioia, M. N. Hossain, and M. Conese, “Biological Properties and Therapeutic Effects of Plant-Derived Nanovesicles,” Open Medicine 15, no. 1 (2020): 1096–1122.

[38] J. Kim, S. Li, S. Zhang, and J. Wang, “Plant-Derived Exosome-Like Nanoparticles and Their Therapeutic Activities,” Asian Journal of Pharmaceutical Sciences 17, no. 1 (2022): 53–69.

[39] M. J. Strowitzki, E. P. Cummins, and C. T. Taylor, “Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?,” Cells 8, no. 5 (2019): 384.

[40] Y. Chen, J. Li, J. Shi, et al., “Ipriflavone Suppresses NLRP3 Inflammasome Activation in Host Response to Biomaterials and Promotes Early Bone Healing,” Journal of Clinical Periodontology 49, no. 8 (2022): 814–827.

[41] S. Adami, L. Bufalino, R. Cervetti, et al., “Ipriflavone Prevents Radial Bone Loss in Postmenopausal Women With Low Bone Mass Over 2 Years,” Osteoporosis International 7, no. 2 (1997): 119–125.

[42] B. H. Arjmandi, R. S. Birnbaum, S. Juma, E. Barengolts, and S. C. Kukreja, “The Synthetic Phytoestrogen, Ipriflavone, and Estrogen Prevent Bone Loss by Different Mechanisms,” Calcified Tissue International 66, no. 1 (2000): 61–65.

[43] G. B. Melis, A. M. Paoletti, A. Cagnacci, et al., “Lack of Any Estrogenic Effect of Ipriflavone in Postmenopausal Women,” Journal of Endocrinological Investigation 15, no. 10 (1992): 755–761.

[44] M. Petilli, G. Fiorelli, S. Benvenuti, et al., “Interactions Between Ipriflavone and the Estrogen Receptor,” Calcified Tissue International 56, no. 2 (1995): 160–165.

[45] R. Missiaen, N. P. Lesner, and M. C. Simon, “HIF: A Master Regulator of Nutrient Availability and Metabolic Cross-Talk in the Tumor Microenvironment,” EMBO Journal 42, no. 6 (2023): e112067.

[46] K. Balamurugan, “HIF-1 at the Crossroads of Hypoxia, Inflammation, and Cancer,” International Journal of Cancer 138, no. 5 (2016): 1058–1066.

[47] A. F. McGettrick and L. A. J. O'Neill, “The Role of HIF in Immunity and Inflammation,” Cell Metabolism 32, no. 4 (2020): 524–536.

[48] G. L. Semenza, “Hypoxia-Inducible Factors: Mediators of Cancer Progression and Targets for Cancer Therapy,” Trends in Pharmacological Sciences 33, no. 4 (2012): 207–214.

[49] J. Liu, F. Wang, H. Luo, et al., “Protective Effect of Butyrate Against Ethanol-Induced Gastric Ulcers in Mice by Promoting the Anti-Inflammatory, Anti-Oxidant and Mucosal Defense Mechanisms,” International Immunopharmacology 30 (2016): 179–187.

[50] P. Alex, N. C. Zachos, T. Nguyen, et al., “Distinct Cytokine Patterns Identified From Multiplex Profiles of Murine DSS and TNBS-Induced Colitis,” Inflammatory Bowel Diseases 15, no. 3 (2009): 341–352.

[51] X. M. Hu, W. Dong, Z. W. Cui, et al., “In Silico Identification of AChE and PARP-1 Dual-Targeted Inhibitors of Alzheimer's Disease,” Journal of Molecular Modeling 24, no. 7 (2018): 151.

[52] M. A. McDonough, V. Li, E. Flashman, et al., “Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),” PNAS 103, no. 26 (2006): 9814–9819.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.